Phosphatidylserine for Sleep, Stress, Brain Health, Adrenal Fatigue and Workout Recovery

Phosphatidylserine (PS) supplementation blunt­s cortisol and ACTH responses to acute physical and psychosocial stress in several controlled trials, often at 400–800 mg/day, and can normalize HPAA hyper‑reactivity in chronically stressed men. Insufficient evidence links PS to the clinical entity called adrenal fatigue.

---

Effects on cortisol

PS trials in humans report consistent reductions in stress‑induced cortisol output and lower ACTH responses, though sample sizes and formulations vary. The strongest quantitative findings come from small exercise and TSST studies showing sizable reductions in peak cortisol or AUC following short‑term PS use.

HPA axis adaptation

Available trials indicate PS acts at or above the pituitary to dampen HPA activation during stress, and can normalize exaggerated responses in chronically stressed subjects. Effects on other endocrine axes appear either absent or inconsistent in the cited trials.

---

Adrenal fatigue evidence

Phosphatidylserine (PS) has been studied across a wide dose range: low single-hundred mg/day (often split doses, weeks–months) to high 600–800 mg/day (short courses). Mid-range PAS combinations (400 mg PS+400 mg PA) normalized cortisol in chronically stressed subjects whereas both lower and larger doses were less effective.

---

Cortisol reduction dosing

This section summarizes clinical protocols that measured cortisol or ACTH responses and lists the daily amount, frequency, and duration used in each trial. A short table compares the main cortisol-focused trials with their dosing and primary endocrine outcome.

All cortisol/ACTH dosing claims in the table are reported directly from the cited trials

.

 

Additional notes on protocols and measurement

• Formulation matters PAS denotes a soy-based phosphatidylserine/phosphatidic acid complex used in several psychosocial stress studies
  1
  2
  .
• Stress model matters Acute psychosocial stress (TSST) and exercise stress protocols used different doses and sometimes different effective ranges
  1
  2
  3
  4
  .

---

Chronic stress protocols

This section focuses on studies that targeted chronically stressed populations and specifies duration and dosing used to evaluate normalization of HPA-axis reactivity.

Clinical chronic-stress trials typically used multi-week supplementation and a once-daily regimen to assess HPA-axis reactivity to an acute stressor. In a randomized trial stratified by chronic stress level, a once-daily PAS 400 (400 mg PS + 400 mg PA) for 42 days normalized ACTH and cortisol responses to an acute psychosocial stressor in the high-chronic-stress subgroup, while PAS 200 (200 mg PS + 200 mg PA) showed no effect under the same protocol

. Another trial using 400 mg PAS daily for three weeks also reported blunted ACTH and cortisol responses to the Trier Social Stress Test, whereas higher PAS doses in that dose-ranging study did not produce the same endocrine blunting . These trials indicate that chronic-stress protocols favor multi-week daily dosing with PAS formulations to achieve HPA-axis normalization .

 

---

Anxiety and mood protocols

This section lists clinical PS regimens used in studies reporting effects on subjective stress, mood, or anxiety-related scales and notes duration and frequency details.

Key mood/anxiety trials and their dosing:

• 300 mg PS daily for one month Young adults high in neuroticism took 300 mg PS per day for one month and reported feeling less stressed and improved mood in a subgroup analysis
  6
  .
• PS 100 mg three times daily for 12 weeks An elderly depression trial used a supplement containing 100 mg PS given three times daily (total 300 mg/day) alongside DHA/EPA for 12 weeks and observed clinical improvement and cortisol rhythm normalization in responders
  7
  .
• 60 mg PS daily for 32 days Elderly patients with major depression received 60 mg PS daily for 32 days; depressive symptoms improved but HPA hormonal patterns did not change
  5
  .

These trials used once- or thrice-daily dosing over weeks to months and show that lower-to-moderate total daily PS (≈60–300 mg/day) has been associated with mood benefits in some populations, whereas hormonal outcomes varied by age and clinical condition

.

 

---

Dose response differences

This section synthesizes observed differences between low, mid, and high doses and explains plausible context dependence in outcomes.

Summary of observed dose–response patterns and distinctions:

• Mid-range PAS efficacy A soy-based PAS dose equivalent to 400 mg PS (plus 400 mg PA) once daily showed consistent HPA-axis normalization for chronically stressed men; PAS 200 was ineffective in that trial
  1
  .
• Inverted-U in PAS dose-ranging In an acute TSST dose–response study, 400 mg PAS blunted ACTH/cortisol but 600 mg and 800 mg PAS did not, suggesting a non-linear (inverted-U) dose response for the PAS formulation in psychosocial stress paradigms
  2
  .
• Higher doses effective in exercise stress Monotherapy PS at 600–800 mg/day for short courses (10 days) blunted exercise-induced cortisol and ACTH responses, showing higher absolute doses can be effective for physiological (exercise) stress models
  3
  4
  .
• Lower doses and mood effects Lower total daily PS (≈60–300 mg/day, often split dosing) over weeks to months has been associated with mood or anxiety symptom improvement in some samples, but hormonal changes were inconsistent across populations and ages
  6
  5
  7
  .

Interpretation and caveats

• Differences in formulation (PS alone versus PAS complex), stressor type (psychosocial TSST versus physical exercise), population (healthy vs chronically stressed vs elderly depressed), and study duration likely explain why a mid-range PAS dose was optimal in some psychosocial stress trials while higher PS monotherapy doses worked in exercise studies
  1
  2
  3
  4
  6
  5
  7
  .
• If precise protocol selection is required for a given clinical aim, the available trials support: PAS 400 once daily for ~6 weeks for chronic psychosocial stress normalization, PS 600–800 mg once daily for ~10 days for blunting exercise-induced cortisol, and PS 300 mg/day (split or once daily) for weeks–months when targeting mood/anxiety outcomes in some populations
  1
  2
  3
  4
  6
  7
  .

If further detail on any specific study protocol is needed, indicate which outcome or population to focus on and the assistant will extract the exact procedural elements from the cited trials.